Company profile
Rallybio Corp
NASDAQ:RLYBBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06435845 | phase2 | terminated | 2024-11-21 | 2025-10-01 | Rallybio | Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization |
| NCT06797375 | phase1 | completed | 2025-04-14 | 2026-02-09 | Rallybio | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants |
FDA applications (0)
No records yet.